GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mymetics Corp (OTCPK:MYMX) » Definitions » Cyclically Adjusted Price-to-FCF

Mymetics (Mymetics) Cyclically Adjusted Price-to-FCF : (As of May. 28, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Mymetics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mymetics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Mymetics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mymetics Cyclically Adjusted Price-to-FCF Chart

Mymetics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mymetics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mymetics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Mymetics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mymetics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mymetics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Mymetics's Cyclically Adjusted Price-to-FCF falls into.



Mymetics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Mymetics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Mymetics's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-2.355/106.5695*106.5695
=-2.355

Current CPI (Sep. 2023) = 106.5695.

Mymetics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 12.682 101.036 13.377
201403 27.161 101.224 28.595
201406 -514.145 101.517 -539.736
201409 0.289 101.247 0.304
201412 2.296 100.704 2.430
201503 0.224 100.339 0.238
201506 11.046 100.464 11.717
201509 -3.888 99.785 -4.152
201512 -2.086 99.386 -2.237
201603 -2.770 99.475 -2.968
201606 -3.697 100.088 -3.936
201609 -2.895 99.604 -3.097
201612 1.967 99.380 2.109
201703 -7.079 100.040 -7.541
201706 0.730 100.285 0.776
201709 -6.164 100.254 -6.552
201712 5.474 100.213 5.821
201803 -5.145 100.836 -5.438
201806 -3.888 101.435 -4.085
201809 -4.546 101.246 -4.785
201812 -4.349 100.906 -4.593
201903 -0.066 101.571 -0.069
201906 -3.553 102.044 -3.711
201909 -2.079 101.396 -2.185
201912 -1.447 101.063 -1.526
202003 -3.342 101.048 -3.525
202006 -2.625 100.743 -2.777
202009 -3.934 100.585 -4.168
202012 -3.039 100.241 -3.231
202103 -2.638 100.800 -2.789
202106 -3.730 101.352 -3.922
202109 -3.566 101.533 -3.743
202112 -3.263 101.776 -3.417
202203 -3.303 103.205 -3.411
202206 -2.572 104.783 -2.616
202209 -3.533 104.835 -3.591
202212 -2.237 104.666 -2.278
202303 -3.368 106.245 -3.378
202306 -4.303 106.576 -4.303
202309 -2.355 106.570 -2.355

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mymetics  (OTCPK:MYMX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Mymetics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Mymetics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mymetics (Mymetics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
c/o Mymetics SA, Route de la Corniche 4, Biopole Center, Epalinges, CHE, CH-1066
Mymetics Corp is a vaccine company and is focused on the research and development of next-generation vaccines for infectious and life-disabling diseases. Its vaccine candidates in the pipeline include HIV-1/AIDS, malaria, and Covid-19, and intranasal influenza, RSV, Chikungunyaand HSV vaccine candidate programs.
Executives
Marcel B. Ruegg director C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Kempers Ronald Hugo Gerard officer: President, CEO, CFO ES GRANDS CHAMPS 12, DULLY V8 1195
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Grant Pickering director, officer: President and CEO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Ulrich Burkhard director C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Jacques Francois Martin officer: CEO 40 QUAI FULCHIRON, LYON I0 69005
Antonius Johannes Stegmann officer: CSO KONINGIN EMMAPLANTSOEN 6, RIJNSBURG P7 2231TZ
Ernest M Stern director 815 CONNECTICUT AVE, NW, SUITE 500, SEYFARTH SHAW LLP, WASHINGTON DC 20006
Thomas Staehelin director POSTFACH 2879, FROMER, SCHULTHEISS & STAEHELIN, BASEL V8 CH-4002
Sylvain Fleury officer: CSO CHEMIN DE VERDONNET 9, LAUSANNE V8 1010
Round Enterprises, Ltd. 10 percent owner C/O BACHMANN TRUST COMPANY LIMITED, FRANCES HOUSE, SIR WILLIAM PLACE, ST. PETER PORT X0 GY1 4EA
Mfc Bancorp Ltd 10 percent owner ROOM 2103 SHANGHAI MART TOWER, 2299 YAN AN ROAD WEST, CHANGNING DISTRICT, SHANGHAI F4 200336
Christian Rochet director, officer: CEO 14, RUE DE LA COLOMBIERE, NYON V8 1260
Robert Zimmer director, officer: vp corp development
Ernst Lubke director, officer: CFO 39, ROUTE D'ARZIER, ARZIER V8 CH-1273